ICU Medical, Incorporated (NASDAQ:ICUI) Director George A. Lopez sold 22,204 shares of ICU Medical stock in a transaction on Tuesday, July 3rd. The stock was sold at an average price of $291.15, for a total value of $6,464,694.60. Following the sale, the director now owns 387,875 shares in the company, valued at $112,929,806.25. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website.
Shares of ICU Medical opened at $289.20 on Friday, Marketbeat Ratings reports. ICU Medical, Incorporated has a 52-week low of $164.00 and a 52-week high of $313.20. The stock has a market capitalization of $5.88 billion, a P/E ratio of 52.32 and a beta of 0.35.
ICU Medical (NASDAQ:ICUI) last announced its quarterly earnings data on Wednesday, May 9th. The medical instruments supplier reported $2.26 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.84 by $0.42. ICU Medical had a return on equity of 9.55% and a net margin of 1.25%. The business had revenue of $372.00 million for the quarter, compared to analysts’ expectations of $346.28 million. During the same period in the previous year, the business posted $1.68 EPS. The firm’s quarterly revenue was up 50.2% compared to the same quarter last year. equities analysts anticipate that ICU Medical, Incorporated will post 6.66 earnings per share for the current fiscal year.
A number of equities research analysts have recently commented on the company. ValuEngine upgraded ICU Medical from a “buy” rating to a “strong-buy” rating in a research note on Saturday, June 2nd. Zacks Investment Research upgraded ICU Medical from a “hold” rating to a “strong-buy” rating and set a $311.00 price objective on the stock in a research note on Wednesday, May 16th. TheStreet cut ICU Medical from an “a” rating to a “c+” rating in a research note on Wednesday, May 9th. Finally, BidaskClub upgraded ICU Medical from a “buy” rating to a “strong-buy” rating in a research note on Saturday, April 28th. One investment analyst has rated the stock with a buy rating and three have assigned a strong buy rating to the company. The company presently has an average rating of “Strong Buy” and an average target price of $311.00.
A number of institutional investors have recently made changes to their positions in the stock. Israel Discount Bank of New York grew its holdings in ICU Medical by 74.8% during the 4th quarter. Israel Discount Bank of New York now owns 853 shares of the medical instruments supplier’s stock valued at $184,000 after buying an additional 365 shares in the last quarter. First Republic Investment Management Inc. purchased a new position in ICU Medical during the 4th quarter valued at about $200,000. Zeke Capital Advisors LLC purchased a new position in ICU Medical during the 1st quarter valued at about $200,000. Eagle Boston Investment Management Inc. purchased a new position in ICU Medical during the 1st quarter valued at about $206,000. Finally, LPL Financial LLC purchased a new position in ICU Medical during the 1st quarter valued at about $218,000. Institutional investors and hedge funds own 72.22% of the company’s stock.
About ICU Medical
ICU Medical, Inc develops, manufactures, and sells medical devices used in vascular therapy, critical care, and oncology applications worldwide. It offers infusion therapy products comprising a tube running from a bottle or plastic bag containing a solution to a catheter inserted in a patient's vein.
Receive News & Ratings for ICU Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ICU Medical and related companies with MarketBeat.com's FREE daily email newsletter.